GSK Sees Much More In Sirtris Than Meets The Eye – IN VIVO Blog

How does an early-stage biotech company, focused on a single set of targets, with a lone compound in early Phase II and everything else preclinical (including its most promising compounds), command a buyout price of $720 million?